CAR T cell therapy shows long-term myeloma remission and specific risks

Recent medical developments regarding CAR T cell therapy for multiple myeloma highlight both long-term efficacy and specific clinical complications. Data presented at the International Myeloma Society Congress regarding Johnson & Johnson’s cilta-cel (ciltacabtagene-autoleucel) shows promising long-term results. In a subset of the phase 2 Cartitude-2 study, 50 percent of patients with relapsed or refractory multiple myeloma remained alive without disease progression for at least five years following a single infusion, without requiring maintenance therapy.

However, research published in Nature Medicine addresses a rare but significant complication: enterocolitis. This inflammation of the small intestine and colon can occur following anti-BCMA CAR T therapy. The study suggests this toxicity is an immune-mediated response characterized by the persistence of CAR T cells within the intestinal mucosa, leading to prolonged inflammatory remodeling. Researchers are investigating the potential use of JAK signaling pathway inhibitors to modulate these inflammatory pathways and manage the condition.